Navigation Links
NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate
Date:12/9/2008

ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) and the University of Massachusetts Medical School announced results from a preclinical study of a Respiratory Syncytial Virus ("RSV") vaccine candidate. Novavax has licensed exclusive worldwide rights from the University of Massachusetts Medical School to certain technology for the development and commercialization of Paramyxovirus vaccines incorporating certain Virus-Like-Particles ("VLPs"). This vaccine candidate is Novavax's first recombinant VLP for the prevention of RSV disease.

The preclinical study evaluated the immunogenicity and efficacy of the RSV VLP vaccine candidate in mice. The VLP contains the matrix (i.e., "core") protein of Newcastle Disease Virus decorated with a human RSV attachment glycoprotein (Ga), which is important for inducing immunity against RSV. In this study, mice were immunized with one of four doses of the RSV VLP vaccine candidate, inactivated RSV, live RSV, or a placebo. The antibody responses to the RSV VLPs were robust and higher than the antibody responses to inactivated or live RSV. Further, antibody titers increased with higher VLP doses.

Subsets of mice that had been immunized with either RSV VLPs via intraperitoneal inoculation or live RSV via intranasal inoculation received a vaccine booster dose and were challenged with live RSV intra-nasally. Unimmunized mice were evaluated as controls. The VLP-immunized mice were protected from RSV replication in the lungs. Further, the lung tissue of these mice showed no evidence of enhanced inflammation after RSV challenge/infection, which has been reported with a formalin-inactivated RSV vaccine.

In summary, the candidate VLP vaccine induced strong antibody responses against RSV, protected mice against RSV replication i
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
2. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
3. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
4. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
5. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
6. Novavax CEO to Present at BIO Investor Forum 2008
7. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
8. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
9. Novavax Announces Closing of $18 Million Registered Direct Offering
10. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"),a Xianyang-based developer, ... and conditions,today announced fiscal results for its second quarter ended June 30, 2009. ... Results, ... Q2 2009 Q2 ...
... ... Web 2.0 Website in an effort to not only provide circuit board assembly and design ... ... value to their current and future customers Surface Mount Solutions (SMS) has launched a new ...
... , , , ... ACTC) announced today that Dr. Robert Lanza, its Chief Scientific Officer, is ... 102 and 55 [Live Saturday 12 pm - 1 pm ET; Replays ... The show focuses on Dr. Lanza,s research at ACTC and his new ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 2Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 3Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 4Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 5Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 6Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 7Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 8Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 9Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 10Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 11Surface Mount Solutions Launches New Website 2Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 2Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 3
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... The way indigenous cultures around the globe use,traditional medicines ... linked to the,natural environment, new research has found. ... threat that comes on top of the challenges posed ... for more than half the world,s population, with 80 ...
... Energy,s (DOE,s) Office of Science and its labs will be ... AAAS Annual Meeting,CHICAGO Attendees of the 2014 AAAS Annual ... DOE,s Office of Science and its labs will play an ... President,s Address ,2014 AAAS co-chair ...
... PITTSBURGH, Feb. 13, 2014 University of Pittsburgh Cancer Institute ... to do new tricks., By screening a library of FDA-approved ... treatment for a rare type of cancer, UPCI scientists were ... the cancer becomes resistant to standard drug treatment., The discovery, ...
Cached Biology News:Environment change threatens indigenous know-how 2Department of Energy speakers and sessions at AAAS 2Department of Energy speakers and sessions at AAAS 3Department of Energy speakers and sessions at AAAS 4Department of Energy speakers and sessions at AAAS 5Department of Energy speakers and sessions at AAAS 6Laboratory detective work points to potential therapy for rare, drug-resistant cancer 2
For testing the AQUA technique on your MS instruments....
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
...
Biology Products: